Given that DR3 stimulation can protect from the onset of type 2 diabetes, we next examined the therapeutic potential of DR3 agonistic treatment in a model of Rag2−/− mice with previously established type 2 diabetes. This evidence concerns the gene TNFRSF25 and type 2 diabetes mellitus.